Aug. 31 at 1:05 PM
$MXCT from ec transcript:
"..And based on the current opportunities in the pipeline, we expect to return back to growth in 2026, with such growth, including continued growth in Asia Pacific, an increasing number of clinical programs utilizing our platform and the launch of a new platform later this year that we believe will add to our top line growth..
Our ability to disclose and discuss these programs is limited by confidential agreements with our customers. However, on Slide 8 of the new deck, we've detailed the 5 programs across 5 SPLs, CRISPR Therapeutics, Wugen, Imugene, Caribou and 1 undisclosed SPL that we believe to enter pivotal studies within this time frame....
My focus of growing MaxCyte with multiple product offerings, while improving operational efficiencies to reduce our annual burn to put us on track towards profitability remains solidly on track...And over time, we believe MaxCyte's platforms and SPL business model will benefit from the growth of the industry..." 👃👀
